Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients Managed at Chinese Academic Centers in the Rituximab Era: A Real-World Study
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 January 2022.
All research outputs
#15,429,718
of 26,166,431 outputs
Outputs from Frontiers in oncology
#4,324
of 22,913 outputs
Outputs of similar age
#240,975
of 529,603 outputs
Outputs of similar age from Frontiers in oncology
#233
of 1,383 outputs
Altmetric has tracked 26,166,431 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,913 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 529,603 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 1,383 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.
